One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Adlai Nortye Group Ltd.
ANL · NGM · Healthcare · Biotechnology
Current price
$11.03
52-week range
$0.88 - $17.25
Market cap
$710.31M
Balance sheet
Healthy
-23.99x Concerning
Net cash $206.12M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -20.2% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 0.9% (peer median: 3.8%).
What this company does
Adlai Nortye Group Ltd.
Adlai Nortye Group Ltd. is a company working to create new medicines to fight cancer. The money they make will come from selling these future cancer treatments. This is important because if their medicines work well, they could help many people and make the company valuable.
How the company got here
Adlai Nortye Group Ltd. started in 2004, originally known as Adlai Nortye Ltd., and has evolved into a clinical-stage biopharmaceutical company focused on creating new treatments for cancer. The company's journey has been marked by its dedication to developing innovative therapies, particularly those targeting specific genetic mutations in cancer cells and harnessing the body's own immune system to fight the disease. A significant recent change was its renaming to Adlai Nortye Group Ltd. in July 2026, reflecting its ongoing growth and strategic direction in the competitive biotech landscape.
What it actually does
Adlai Nortye Group Ltd. is in the business of discovering and developing new medicines to treat cancer. Think of them like a chef experimenting with new recipes, but instead of food, they're creating potential drugs. These aren't drugs you can buy off the shelf; they are experimental treatments that are currently being tested in clinical trials to see if they are safe and effective for patients. The company's main focus is on two key areas: therapies that target a specific group of genes called RAS, which are often mutated in many cancers, and advanced treatments that use the immune system to attack cancer cells.
RAS-Targeting Therapies
This part of Adlai Nortye's business is dedicated to developing drugs that specifically target the RAS gene family. Mutations in RAS genes are common drivers of cancer growth, so by inhibiting these mutated genes, the company aims to stop cancer from spreading. Their pipeline includes AN9025, a pill designed to inhibit all forms of activated RAS, and AN4035, which is an antibody-drug conjugate. An antibody-drug conjugate is like a guided missile for cancer treatment; it uses an antibody to find cancer cells and then delivers a powerful drug directly to them, in this case, a RAS-inhibiting drug, to minimize harm to healthy cells.
Next-Generation Cancer Immunotherapies
This segment focuses on harnessing the patient's own immune system to fight cancer, a field known as immuno-oncology. Adlai Nortye is developing several experimental treatments here. AN8025 is a complex protein designed to stimulate immune cells (T-cells) and other cells that help the immune system recognize cancer. AN0025 is a small molecule drug aimed at blocking a specific pathway (EP4) that can suppress the immune response against tumors. Lastly, AN4005 is an oral medication that works by inhibiting PD-L1, a protein that cancer cells use to hide from the immune system, thereby helping the body's defenses to attack the cancer.
What management is betting on now
Adlai Nortye's leadership is focused on advancing its pipeline of innovative cancer therapies through clinical trials. Their strategy hinges on the potential of their RAS-targeting drugs and their next-generation immunotherapies to address significant unmet needs in cancer treatment. By operating a robust research and development platform with facilities in both the United States and China, the company aims to efficiently move these promising drug candidates towards potential approval and ultimately to patients who need them.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $11.03
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $206.1M - more cash than debt. Interest coverage -24.0x.
Net debt
$-206.12M
Interest coverage
-23.99x
Adlai Nortye Group Ltd.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ANL
BASELINE
Adlai Nortye Group Ltd.
Total debt $26.70M Interest coverage -23.99x This is the baseline the peer rows are being compared against.
Total debt $1.19B Interest coverage -48.80x Neither company has much profit cushion over interest right now.
Total debt $73.41M Interest coverage -15.10x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -21.04x Neither company has much profit cushion over interest right now.
Total debt $31.99M Interest coverage -19.77x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ANL
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -20.2% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 0.9% (peer median: 3.8%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-37.48x
P/B
3.31x
P/S
39.34x
EV/EBITDA
-23.29x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
100.0%
Operating margin
-44.2%
Net margin
-124.8%
ROE
-20.2%
ROA
-8.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.12x
Current ratio
9.55x
Quick ratio
9.24x
Total debt
$26.70M
Total cash
$232.82M
Growth
How the business has been compounding
Revenue TTM
$18.06M
Revenue 5Y CAGR
—
EPS TTM
-0.66
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-33.45M
Free CF TTM
$-33.64M
FCF margin
-186.3%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—